Biopsy Devices – Market Insights – United States

The US biopsy device market has shown strong recovery from the impacts of the COVID-19 pandemic and is anticipated to resume prepandemic growth trends in the near term, with subsequent slow growth through 2032. Growth over the forecast period will be driven mainly by the development of more accurate testing methods, advanced imaging technologies, as well as rising cancer awareness and updated recommendations to screening guidelines.

This Medtech 360 Report provides comprehensive data and analysis on the state of the market for biopsy devices in the US from 2019 through 2032.

Biopsy volumes in the US will be impacted by various initiatives in cancer screening programs.

What cancer screening programs have been launched in recent years, and how have they impacted the market?

What are the latest CRC screening recommendations? How will they impact overall procedure volumes?

How are breast cancer and cervical cancer screening programs affecting market dynamics in the US?

Which device markets will be most impacted by updated screening recommendations and screening innovations?

Advancements in imaging technologies will support the overall growth in the US biopsy device market.

How are improvements in imaging technologies impacting screening and procedure volumes?

What types of imaging technologies are driving the growth of the biopsy device market in the US?

Novel early-detection alternative technologies to tissue biopsy, including AI and MIS diagnostic tests, are being adopted by physicians in the US.

What minimally invasive technologies are currently available in the US?

What is the potential impact of AI-based platforms on biopsy procedure volumes?

How will the adoption of alternative technologies in early detection for diseases impact the biopsy device market in the long run?

Adoption of liquid biopsy is increasing in the US.

Which biopsy device market segments are being affected by the emergence of FDA-approved liquid biopsy tests?

Will the uptake of liquid biopsy assays challenge or drive the growth of conventional biopsy devices?

Table of contents